The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global (CGB) shares are on the rise today after the Thailand Government changed regulations for hemp
  • From Friday, January 29, the Thailand Government will begin processing applications for hemp licences
  • Prior to the changes, hemp licences were only issued to those undertaking research programs in Thailand
  • Cann’s subsidiary, Cann Global Thailand, is expected to benefit from the new regulations and will be able to offer its services to multiple companies
  • On the market today, Cann Global is up 6.25 per cent and trading at 0.9 cents per share

Cann Global (CGB) shares are on the rise today after Thailand’s regulation for hemp changes.

From Friday, January 29, the Thailand Government will begin processing applications for licences to produce, import, export, distribute and possess hemp.

This is a significant step for Thailand’s hemp industry.

Prior to the changes, hemp licences were only issued to those undertaking research programs in Thailand.

Cann’s 55 per cent owned subsidiary, Cann Global Thailand (CGT) has been providing technical support for the last year to AA Bio Co, relating to its hemp cultivation research program with Uttaradit Rajajaht University.

CGT was created to provide a full cultivation and extraction service for Thai clients. In particular, CGT will provide seeds, organic growing materials, extraction equipment and information technology systems to manage cultivations.

“We have a full-time expert team in place who have been preparing the groundwork and establishing partnerships and infrastructure to allow CGT to immediately capitalise on these regulatory changes,” Managing Director Sholom Feldman said.

“The regulatory changes open the market up significantly to benefit CGT’s service-based revenue model and we look forward to maximising the value of our first-mover status in this large new market,” he added.

On the market today, Cann Global is up 6.25 per cent and trading at 0.9 cents per share at 1:10 pm AEDT.

CGB by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a…

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…